Empirical Finance’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $929K | Sell |
5,070
-6
| -0.1% | -$1.11K | 0.04% | 313 |
|
|
2025
Q4 | $893K | Sell |
5,076
-210
| -4% | -$34.3K | 0.04% | 308 |
|
|
2025
Q3 | $740K | Buy |
5,286
+53
| +1% | +$7.16K | 0.04% | 365 |
|
|
2025
Q2 | $657K | Buy |
5,233
+31
| +0.6% | +$3.86K | 0.03% | 381 |
|
|
2025
Q1 | $712K | Buy |
5,202
+187
| +4% | +$26.7K | 0.04% | 343 |
|
|
2024
Q4 | $767K | Sell |
5,015
-55
| -1% | -$9.28K | 0.04% | 322 |
|
|
2024
Q3 | $983K | Buy |
5,070
+101
| +2% | +$21.1K | 0.06% | 281 |
|
|
2024
Q2 | $1.15M | Sell |
4,969
-374
| -7% | -$81.3K | 0.07% | 237 |
|
|
2024
Q1 | $1.15M | Buy |
5,343
+178
| +3% | +$41.7K | 0.07% | 251 |
|
|
2023
Q4 | $1.34M | Buy |
5,165
+21
| +0.4% | +$5.16K | 0.09% | 201 |
|
|
2023
Q3 | $1.32M | Buy |
5,144
+430
| +9% | +$115K | 0.1% | 186 |
|
|
2023
Q2 | $1.34M | Buy |
4,714
+531
| +13% | +$158K | 0.1% | 178 |
|
|
2023
Q1 | $1.16M | Buy |
4,183
+164
| +4% | +$45.4K | 0.11% | 177 |
|
|
2022
Q4 | $1.11M | Buy |
4,019
+289
| +8% | +$81.6K | 0.12% | 172 |
|
|
2022
Q3 | $996K | Buy |
3,730
+578
| +18% | +$123K | 0.12% | 165 |
|
|
2022
Q2 | $643K | Buy |
3,152
+157
| +5% | +$32.1K | 0.08% | 231 |
|
|
2022
Q1 | $631K | Buy |
2,995
+562
| +23% | +$122K | 0.07% | 251 |
|
|
2021
Q4 | $584K | Buy |
2,433
+395
| +19% | +$102K | 0.07% | 260 |
|
|
2021
Q3 | $577K | Sell |
2,038
-1,919
| -48% | -$629K | 0.09% | 238 |
|
|
2021
Q2 | $1.37M | Sell |
3,957
-5,325
| -57% | -$1.61M | 0.22% | 95 |
|
|
2021
Q1 | $2.27M | Hold |
9,282
| – | – | 0.4% | 61 |
|
|
2020
Q4 | $2.27M | Buy |
9,282
+260
| +3% | +$67.1K | 0.4% | 61 |
|
|
2020
Q3 | $2.56M | Sell |
9,022
-724
| -7% | -$202K | 0.55% | 33 |
|
|
2020
Q2 | $2.61M | Buy |
9,746
+223
| +2% | +$67K | 0.67% | 23 |
|
|
2020
Q1 | $3.01M | Buy |
9,523
+4,157
| +77% | +$1.26M | 0.94% | 15 |
|
|
2019
Q4 | $1.59M | Sell |
5,366
-975
| -15% | -$271K | 0.39% | 45 |
|
|
2019
Q3 | $1.48M | Buy |
+6,341
| New | +$1.48M | 0.41% | 40 |
|
|
2018
Q3 | – | Sell |
-2,595
| Closed | -$753K | – | 154 |
|
|
2018
Q2 | $753K | Buy |
+2,595
| New | +$730K | 0.19% | 80 |
|
|
2018
Q1 | – | Sell |
-3,607
| Closed | -$1.15M | – | 164 |
|
|
2017
Q4 | $1.15M | Sell |
3,607
-231
| -6% | -$74.1K | 0.38% | 76 |
|
|
2017
Q3 | $1.2M | Hold |
3,838
| – | – | 0.41% | 67 |
|
|
2017
Q2 | $1.04M | Buy |
3,838
+127
| +3% | +$33.6K | 0.4% | 69 |
|
|
2017
Q1 | $1.01M | Buy |
3,711
+3,607
| +3,468% | +$1.02M | 0.47% | 59 |
|
|
2016
Q4 | $30K | Buy |
+104
| New | +$30.8K | 0.02% | 144 |
|
Other funds holding BIIB
VCM
VPM
Empirical Finance's BIIB Position: Q1 2026 in Review
Empirical Finance reduced its Biogen (BIIB) stake by 0.12% in Q1 2026, selling an estimated $1.11K and leaving 5,070 shares worth $929K. The position accounts for 0.04% of the portfolio, ranked #313.
Empirical Finance first reported a position in BIIB in Q4 2016 and has held it in 33 quarters since. The position peaked at $3.01M in Q1 2020. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Empirical Finance held 5,070 shares of Biogen worth $929K as of Q1 2026.
- Empirical Finance sold 6 Biogen shares in Q1 2026, an estimated $1.11K.
- Biogen made up 0.04% of Empirical Finance's portfolio in Q1 2026, its #313 holding.
- Empirical Finance first reported a position in Biogen in Q4 2016 and has held it in 33 quarters since.
- Empirical Finance's Biogen position peaked at $3.01M in Q1 2020.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Empirical Finance's 13F filing for Q1 2026, filed 14 May 2026.